Restaurant Brands Intl Stock (OTC: RSTRF)

Latest news for Restaurant Brands Intl (OTC:RSTRF) Stock

Restaurant Brands Intl

Restaurant Brands International LP is a Canada-based firm. It owns, operates and franchises quick-service restaurants and possesses market recognition. The company has five segments TH, BK, PLK, FHS and INTL. It derives maximum profit from TH segment.

News

Markets

Media

General

BRK-A

BRK-B

RSTRF

SBUX

Ariel Chairman John Rogers Thinks Current Market Is &#39;Once In A Lifetime Opportunity To Buy Stocks&#39;

Restaurants

Legal

Burger King Sued Over &#39;Impossible Whopper&#39; Possibly Not Being Vegan

Intraday Update

Movers

Trading Ideas

ACHN

ACKRF

ACNDF

ACRL

ADDDF

ADDYY

ADUS

AEGXF

AGYS

AKRO

ANIK

ANIP

APHD

APPN

ARES

ARRY

ARVN

ASMIY

ATEC

AUDC

AVLR

AZPN

AZUL

BCBF

BEIJF

BFAM

BGEM

BKAHF

BLUSF

BPYPP

BTDPY

BYND

CACI

CBHMF

CBHMY

CCNI

CCOI

CHCT

CIADY

CMPGF

CMPGY

CNNEF

CNSWF

COLFF

COWN

CPRT

CRVL

CRWD

CSGS

CSTL

CTLT

CWST

CYBR

CYTK

DANOY

DCOM

DENN

EGFEY

EGHT

EGOV

EHTH

ENSG

EPAM

ESTC

EVBG

EXETF

EXPE

EXPO

FFDF

FICO

FISV

FLXT

FMCI

Companies That Achieved 52-Week Highs Friday

Restaurant Brands International LP

Biotech

Merck Exec Says Targeting Next Year's RSV Season In U.S. For RSV Antibody

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.50% to 40,742.44 while the NASDAQ slipped 0.01% to 17,370.07. The S&amp;P 500 also rose, gaining, 0.22% to 5,475.80.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036066/top-3-financials-stocks-which-could-rescue-your-portfolio-for-july">Top 3 Financials Stocks Which Could Rescue Your Portfolio For July</a>
Leading and Lagging Sectors Financials shares jumped by 1.3% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 1%.
Top Headline
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected second-quarter financial results.
Pfizer reported second-quarter adjusted EPS of 60 cents, down 11% year over year, beating the consensus of 46 cents. The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
Pfizer updated its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion. Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares shot up 158% to $3.0500 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Shares of Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) got a boost, surging 100% to $0.1766. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares were also up, gaining 44% to $2.44 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
</ul>
Equities Trading DOWN
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dropped 79% to $12.37. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>Shares of NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) were down 35% to $10.78. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) was down, falling 31% to $0.7169 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036664/jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-ener">Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: &#8216;It&#8217;s Up A Huge Amount&#8217;</a>
Commodities In commodity news, oil traded down 1.3% to $74.81 while gold traded up 0.5% at $2,438.40.
Silver traded up 1% to $28.145 on Tuesday, while copper fell 0.9% to $4.0485.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.7%, Germany's DAX gained 0.7% and France's CAC 40 climbed 0.7%. Spain's IBEX 35 Index rose 0.9%, while London's FTSE 100 fell 0.1%.
The Euro Area GDP grew by 0.3% on quarter during the second quarter, the same as in the prior period but above expectations of 0.2%. The economic sentiment indicator in the Eurozone slipped to 95.8 in July from 95.9 in the prior month, while services sentiment indicator fell to 4.8 in July from a revised 6.2 in the prior month.
The German economy shrank 0.1% on quarter during the second quarter, compared to a 0.2% increase in the prior quarter, while Spanish economy expanded by 0.8% quarter-over-quarter in the second quarter. The French economy grew by 0.3% quarter-over-quarter during the second quarter.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.15%, Hong Kong's Hang Seng Index dipping 1.37%, China's Shanghai Composite Index falling 0.43% and India's S&amp;P BSE Sensex rising 0.12%.
Japanese unemployment rate came in at 2.5% for June, versus market projections of 2.6%.
Economics
<ul>
<li>The number of job openings came in at 8.184 million in June compared to a revised 8.23 million in May.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose 6.8% year-over-year in May versus a revised 7.3% gain in April.</li>
<li>The FHFA house price index came in unchanged for May.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40036623/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

Earnings

Eurozone

Commodities

ATPC

CNSP

IMNN

NIPG

PCSA

Dow Jumps 200 Points; Pfizer Earnings Top Views

WIIM

Ecolab shares are trading lower after the company reported worse-than-expected Q2 sales results.

NIP Group Shares Resumed Trade

Guidance

Sysco Exec Says Corporate Expenses Were Down 10% YoY In The Quarter

VBIV

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: News and Resumption Times

Crane shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company raised the midpoint of its FY24 EPS guidance.

RGEN

Repligen shares are trading higher. The company reported Q2 financial results.

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

VUZI

Vuzix's Moviynt Subsidiary Receives SAP Certification For Mobilium Gateway 3.0 Solution With S/4HANA Cloud Private Edition; Aims To Bridge Mobile Devices And ERP Systems To Enhance Workflow Efficiency

Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) reported fourth-quarter FY24 sales growth of 4.2% to $20.556 billion,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40034864/sysco-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener"> missing the analyst consensus estimate of $20.573 billion.</a>
U.S. Foodservice operations sales rose 4.9% Y/Y, and International Foodservice sales grew 3.8%.
Gross profit increased 4.2% Y/Y to $3.8 billion, and the gross margin compressed 1 basis point to 18.7%.
The operating margin contracted 14 basis points to 4.8%, and operating income for the quarter rose 1.2% to $977 million. Non-GAAP operating margin expanded 11 basis points to 5.3%.
Adjusted EBITDA increased 5.4% Y/Y to $1.3 billion in the quarter. Adjusted EPS of $1.39 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of $1.38.</a>
Sysco held $696 million in cash and equivalents as of June 29. Operating cash flow for FY24 totaled $3 billion, with a free cash flow of $2.2 billion.
The company returned approximately $2.2 billion to shareholders via $1.2 billion of share repurchases and $1.0 billion of dividends.
&#8220;Fiscal 2025 kicks off the first year of our three-year financial growth algorithm. Our plans for consistent top- and bottom-line growth are built on our expectations for sustainable growth, operational excellence, and a balanced capital return profile. This long-term view reflects an expected compounded annual growth rate of&nbsp;4%-6%&nbsp;for net sales,&nbsp;6%-8%&nbsp;for adjusted EPS, and&nbsp;9-11%&nbsp;total shareholder returns,&#8221; said Kenny Cheung, Sysco&#8217;s Chief Financial Officer.
Price Action: SYY shares are trading higher by 0.79% at $73.84 at the last check Tuesday.
Photo via Wikimedia Commons

Equities

Food Products Distributor Sysco Misses On Revenue But Delivers on Q4 Earnings – What's in Store for FY25?

Sysco Exec Says Traffic To Restaurants Was Down About 3% YoY For Q4

HAYW

Hayward shares are trading higher after the company reported better-than-expected Q2 EPS results.

NIP Group Shares Halted On Circuit Breaker, Stock Now Down -34.7%

Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has outperformed the market over the past 5 years by 10.17% on an annualized basis producing an average annual return of 24.17%. Currently, Alphabet has a market capitalization of $2.10 trillion. 
Buying $100 In GOOGL: If an investor had bought $100 of GOOGL stock 5 years ago, it would be worth $284.89 today based on a price of $170.44 for GOOGL at the time of writing.
<h3>Alphabet's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722348142_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GOOGL

$100 Invested In Alphabet 5 Years Ago Would Be Worth This Much Today

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 9.51%. Currently, Honeywell Intl has a market capitalization of $131.71 billion. 
Buying $100 In HON: If an investor had bought $100 of HON stock 20 years ago, it would be worth $595.33 today based on a price of $202.73 for HON at the time of writing.
<h3>Honeywell Intl's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722348137_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $600 Today

Cantor Fitzgerald analyst Louise Chen reiterates Innoviva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVA#NASDAQ">INVA</a>) with a Overweight.

INVA

Cantor Fitzgerald Reiterates Overweight on Innoviva

In the last three months, 14 analysts have published ratings on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $183.5, a high estimate of $215.00, and a low estimate of $150.00. This current average represents a 0.89% decrease from the previous average price target of $185.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1722348093_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Johnson &amp; Johnson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Johnson &amp; Johnson displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 4.31%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Johnson &amp; Johnson's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.62%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Johnson &amp; Johnson's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 14 Analyst Recommendations For Johnson & Johnson

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.64, with a high estimate of $25.00 and a low estimate of $8.00. This current average has decreased by 18.83% from the previous average price target of $20.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722348083_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Sage Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Sell</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sage Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sage Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Sage Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Sage Therapeutics: A Closer Look</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 139.89%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -1372.86%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -14.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sage Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.15%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAGE

Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts

Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $182.4, a high estimate of $210.00, and a low estimate of $145.00. Observing a 11.85% increase, the current average has risen from the previous average price target of $163.07. 
<img src="https://www.benzinga.com/files/images/story/2024/1722348071_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Royal Caribbean Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Greg Badishkanian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$204.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>John Staszak</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Royal Caribbean Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Royal Caribbean Gr compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Royal Caribbean Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Royal Caribbean Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Royal Caribbean Gr analyst ratings.</a>
<h2>Delving into Royal Caribbean Gr's Background</h2>
Royal Caribbean is the world's second-largest cruise company, operating 65 ships across five global and partner brands in the cruise vacation industry, with eight more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
<h3>Royal Caribbean Gr's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Royal Caribbean Gr showcased positive performance, achieving a revenue growth rate of 16.66% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Royal Caribbean Gr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Royal Caribbean Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Royal Caribbean Gr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Royal Caribbean Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.62.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Royal Caribbean Gr Stands With Analysts

Restaurant Brands International: Attractive Despite Potentially Softening Growth

Restaurant Brands International Limited Partnership goes ex dividend tomorrow

Restaurant Brands: Healthy Performance And Outlook

WING

Ariel Investments Chairman, John Rogers, <a href="https://www.cnbc.com/2020/03/25/this-is-a-once-in-a-lifetime-buying-opportunity-like-87-and-08-says-ariels-john-rogers.html">advocates</a> making the most of the rout in equities, advising investors to consider it the opportunity of a lifetime.

<h3>Once In A Lifetime Opportunity</h3>

The sharp sell-off in equities is a buying opportunity that does not present itself often, and investors should take advantage of this&nbsp;opportunity. Appearing on CNBC Wednesday night,&nbsp;Rogers shared his point of view, &ldquo;I think this is a maybe once in a lifetime opportunity to buy stocks at bargain prices.&rdquo; He quoted Sir John Templeton, a famed investor, &ldquo;Buy when there&rsquo;s maximum pessimism.&rdquo;

<h3>The Voice Of Experience&nbsp;</h3>

Rogers is the founder, chairman and CEO of Ariel Investments and also the company&rsquo;s chief investment officer. He has been featured alongside Warren Buffet, Ben Graham and Sir John Templeton in the book &ldquo;The World&rsquo;s 99 Greatest Investors,&rdquo; written by Magnus Angenfelt.&nbsp;

Highlighting his&nbsp;background, Rogers advised, &ldquo;We&rsquo;ve been around 37 years at Ariel, and I know I said that &lsquo;once in a lifetime&rsquo; chance to buy in &rsquo;87 and again in 2008, but I do really think this is an opportunity to take advantage of the volatility, and take advantage of the market.&rdquo;

<h3>Budding Optimism Among Analysts</h3>

The Chief Investment Officer of Miller Value Partners said on CNBC&rsquo;s &ldquo;The Exchange,&rdquo;&nbsp;&ldquo;I think this is an exceptional buying opportunity.&rdquo; Hedge fund Pershing Square&rsquo;s manager Bill Ackman also revealed that he had exited market hedge positions earlier in the week and used the resulting $2 billion to accumulate fresh and existing positions.

Ackman is investing in Agilent Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="/stock/A#NYSE">A</a>), Berkshire Hathaway Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brk-a#NYSE">BRK-A</a>) (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brk-b#NYSE">BRK-B</a>), Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="/stock/HLT#NYSE">HLT</a>), Lowe&rsquo;s Companies Inc. (NYSE:<a class="ticker" href="/stock/LOW#NYSE">LOW</a>)&nbsp;and Restaurant Brands International Limited Partnership&nbsp;(OTC:<a class="ticker" href="/stock/RSTRF#OTC">RSTRF</a>). His fund has also reestablished investments in Starbucks Corporation (NASDAQ:<a class="ticker" href="/stock/SBUX#NASDAQ">SBUX</a>), which it had closed in January.&nbsp;

DataTrek Research co-founder Nicholas Colas, who follows a trading playbook based on market action, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/03/15663916/the-2008-playbook-suggests-we-havent-seen-the-market-bottom-yet">warned</a>&nbsp;that investors have not yet seen the market bottom.

The Dow Jones Industrial Average and S&amp;P500 had&nbsp;both rallied for two consecutive days as of&nbsp;Wednesday, the first time since February,&nbsp;even though the two indexes are at levels below their February all-time highs due to the impact of the <a href="https://www.benzinga.com/coronavirus-covid-19/">COVID-19 pandemic</a>.

Photo Credit: Screenshot of Online Stream.

Ariel Chairman John Rogers Thinks Current Market Is 'Once In A Lifetime Opportunity To Buy Stocks'

Florida-based fast-food chain Burger King has been taken to court by a Georgia man for falsely advertising its &ldquo;Impossible Whopper&rdquo; burger as meat-free.

<h3>What Happened</h3>

Philip Williams, in his&nbsp;<a href="https://www.classaction.org/media/williams-v-burger-king-corporation.pdf">petition</a>, said that Burger King violated Florida&rsquo;s Deceptive and Unfair Trade Practices Act by misleading customers to believe that the burger is &ldquo;meat-free.&rdquo;

Williams accused that while Burger King uses a vegan meat alternative made by California-based Impossible Foods, it uses the same grills to cook these vegan patties that it uses for other meat-based burgers.

<h3>Not Really Meat Free</h3>

Burger King&nbsp;<a href="https://mobile.bk.com/menu-item/impossible-whopper">advertises</a>&nbsp;the burger as &ldquo;100% Whopper, 0% Beef&rdquo; on its website, but doesn&rsquo;t use the term &ldquo;vegan&rdquo; in its advertising. In fact, the company mentions &ldquo;creamy mayonnaise&rdquo; as one of the ingredients, with egg marked as an allergen contained in the product.

The website says that if customers want a &ldquo;meat-free option,&rdquo; they can request a different method of preparation, the Washington Post&nbsp;<a href="https://www.washingtonpost.com/food/2019/11/19/vegan-sues-burger-king-claiming-meatless-impossible-whopper-is-contaminated-by-beef-fat/">noted</a>.

Concerns over the meat-free burger being cooked on the same grills as the ones with meat were raised even before the burger launched in August, Bloomberg&nbsp;<a href="https://www.bloomberg.com/news/articles/2019-08-01/impossible-burgers-touching-beef-whoppers-have-vegans-on-alert">reported</a>&nbsp;at the time.

<h3>Price Action</h3>

Restaurant Brands International Inc (OTC:<a class="ticker" href="/stock/RSTRF#OTC">RSTRF</a>), Burger King&#39;s parent company, closed 0.092% higher at $87.31 on the Toronto Stock Exchange on Tuesday.

Impossible Foods is a privately traded company. As Barron&rsquo;s&nbsp;<a href="https://www.barrons.com/articles/beyond-meat-stock-burger-king-impossible-whipper-plant-based-protein-vegan-51574196190">noted</a>, its competitor Beyond Meat&rsquo;s shares fell 2.97% to $77.35 on Tuesday following the news.

Burger King Sued Over 'Impossible Whopper' Possibly Not Being Vegan

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Restaurant Brands Intl

News

Latest news for Restaurant Brands Intl (OTC:RSTRF) Stock

Thursday, March 26, 2020

Wednesday, November 20, 2019

Friday, July 26, 2019